Source:http://linkedlifedata.com/resource/pubmed/id/12704416
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2003-4-21
|
| pubmed:abstractText |
Transfer of the sodium iodide symporter (hNIS) has been proposed as a new principle of cancer gene therapy. Using clinically relevant doses of (131)I for the treatment of NIS-expressing prostate carcinoma cells, we investigated the kinetics and the absorbed doses obtained in these tumors. hNIS-expressing cell lines accumulated up to 200 times more iodide when compared to wild-type cells. However, a rapid efflux of the radioactivity (80%) occurred during the first 20 min after replacement of the medium. In rats, the hNIS-expressing tumors accumulated up to 20 times more iodide when compared to contralateral transplanted wild-type tumors. After 24 h and doses of 550, 1200 or 2400 MBq/m(2) hNIS-expressing tumors lost 89, 89 and 91% of the initial activity, respectively. Dosimetric calculations showed that 1200 MBq/m(2) resulted in 3+/-0.5 Gy (wild-type tumor 0.15+/-0.1 Gy) and 2400 MBq/m(2) resulted in 3.1+/-0.9 Gy (wild-type tumor 0.26+/-0.02 Gy). Although transduction of the hNIS gene induces iodide transport in rat prostate adenocarcinoma a rapid efflux occurs, which leads to a low absorbed dose in genetically modified tumors. With regard to a therapeutic application additional conditions need to be defined leading to iodide trapping.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0969-7128
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
774-80
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12704416-Absorption,
pubmed-meshheading:12704416-Adenocarcinoma,
pubmed-meshheading:12704416-Animals,
pubmed-meshheading:12704416-Biological Transport,
pubmed-meshheading:12704416-Gene Therapy,
pubmed-meshheading:12704416-Genetic Vectors,
pubmed-meshheading:12704416-Humans,
pubmed-meshheading:12704416-Immunohistochemistry,
pubmed-meshheading:12704416-Iodides,
pubmed-meshheading:12704416-Iodine Radioisotopes,
pubmed-meshheading:12704416-Male,
pubmed-meshheading:12704416-Neoplasms, Experimental,
pubmed-meshheading:12704416-Prostatic Neoplasms,
pubmed-meshheading:12704416-Rats,
pubmed-meshheading:12704416-Rats, Inbred Strains,
pubmed-meshheading:12704416-Retroviridae,
pubmed-meshheading:12704416-Symporters,
pubmed-meshheading:12704416-Transduction, Genetic,
pubmed-meshheading:12704416-Tumor Cells, Cultured
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose.
|
| pubmed:affiliation |
Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|